The optimal strategy for treating persistent atrial fibrillation with radiofrequency catheter ablation (a randomized controlled trial)

Not Applicable

Recruiting

Conditions: Diseases of the circulatory system

Registration Number: KCT0008560

Lead Sponsor: Asan Medical Center

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 240

Inclusion Criteria

Adults between the ages of 18 and 85
Diagnosis of persistent atrial fibrillation, which is confirmed by 12-lead electrocardiogram or Holter monitoring lasting for more than 7 days, event recorder, or exercise stress test
Resistance or intolerance to at least one class I or III antiarrhythmic drug
Patients undergoing the first eablation procedure for atrial fibrillation
Patients who have provided informed consent to participate in the study.

Exclusion Criteria

Patients who refuse to participate in the study
Patients under 18 or over 85 years of age
Left atrial diameter of 60mm or greater
Atrial thrombus
Contraindication to anticoagulation therapy
Previous surgical or procedural treatment for atrial fibrillation
Severe valvular heart disease, mitral stenosis, or mechanical prosthetic valve
Left atrial diameter of 60mm or greater
NYHA class IV heart failure
Recent thoracic surgery within the past 3 months
Scheduled thoracic surgery within the next 3 months
Pulmonary veins observed on CT that are anatomically unsuitable for the procedure
End-stage or severe heart failure (estimated glomerular filtration rate [MDRD method] < 30mL/min/1.73m)
Pregnant or breastfeeding women
NYHA class IV heart failure
Acute coronary syndrome within the past 3 months
Patients with a life expectancy of less than 1 year.

Study & Design

Study Type: Interventional Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The incidence of atrial tachyarrhythmia, including atrial fibrillation, atrial flutter, and atrial tachycardia, lasting for 30 seconds or longer, that occurs after a blanking period of several months and while the medication is discontinued.

Secondary Outcome Measures